Evaluation of different approaches for establishing an in-vitro/in-vivo correlation for a BCS class IV molecule case study: Candesartan Cilexetil tablets

• In: Poster presentation
• At: Buenos Aires (Argentina) (2016)
• Type: Poster
• Poster code: POS-FDP-007
• By: FíGOLI, Gustavo (Phoenix, Buenos Aires, Argentina)
• Co-author(s): Gustavo Fígoli:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Fernando Montini:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Daniel Goicochea:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Florencia De Blasiis:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Silvana Quattrocchi:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|James Butler:Biopharmaceutics, Product Development,GSK,Ware,United Kingdom|Florencia Esquivel:Medical Department ,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Alejandro Di Cio Gimena:Medical Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Cristian Oddo:Development Department,Phoenix SAICyF,Villa de Mayo –Buenos Aires,Argentina|Rajesh Patel:Classic and Established Products,GSK,London,United Kingdom
  
• Abstract:

  IVIVC supports Oral Solid Dose optimization and could help to reduce the amount of in-vivo trials in humans, fixes dissolution acceptance criteria, and can be used as a surrogate for further bioequivalence studies. Candesartan cilexetil a BCS Class IV was used for this study.

  Different formulations of candesartan cilexetil and candesartan cilexetil

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login